罗格列酮对DM2合并CHD患者炎症因子影响的临床观察

目的：观察罗格列酮对2型糖尿病（DM2）合并冠心病（CHD）患者高敏C反应蛋白（hs-CRP）、白细胞介素6（IL-6）及基质金属蛋白酶-9（MMP-9）水平的影响。方法：采用酶联免疫吸附法分别测定46例DM2合并CHD患者（DM组）,40例非糖尿病CHD患者（NDM组）及38例健康对照者的血清hs-CRP、IL-6及MMP-9水平。DM组患者给予罗格列酮（4mg/d）治疗1个月后测定血清hs-CRP、IL-6及MMP-9水平。结果：DM组患者血清hs-CRP、IL-6及MMP-9水平均显著高于NDM组及对照组（P〈0.05）,DM组患者罗格列酮治疗1月后血清hs-CRP、IL-6及MMP-9水平均明显下降（P〈0.05）。结论：罗格列酮可降低DM2合并CHD患者的炎症因子水平,具有独立于降糖作用之外的抗动脉粥样硬化作用。

Effects of Rosiglitazone on Inflammatory Factors in Patients with Type 2 Diabetes Mellitus Complicated with Coronary Artery Disease

Objective To investigate the effect of rosiglitazone on serum levels of high sensitive C-reactive protein（hs-CRP）,interleukin-6（IL-6）and matrix metalloproteinase-9（MMP-9）in patients with type 2 diabetes mellitus（DM2）complicated with coronary heart disease（CHD）.Methods The serum hs-CRP,IL-6 and MMP-9 levels were determined with ELISA in 46 patients with DM2 complicated with CHD,40 CHD patients without DM and 38 controls.All DM patients were treated with 4mg rosiglitazone daily,after 1 month treatment the inflammatory factors were determined for the second time.Results The serum hs-CRP,IL-6 and MMP-9 levels were all significantly higher in DM group than those in NDM group and control group（P0.05）.The serum hs-CRP,IL-6 and MMP-9 decreased significantly after rosiglitazone treatment for 1 month（P0.05）.Conclusion Rosiglitazone could decrease the levels of inflammatory factors.Rosiglitazone had anti-atherosclerotic effect independent of its lowering blood glucose action.